

Company Presentation

Ð

.

4

1th

September 2022



VISION

Build India's Largest Digital Healthcare Platform

MISSION

Simplifying Healthcare, Impacting Lives

API Holdings





Massive Healthcare Market in India Laying a Multitude of Opportunities

India Healthcare Market Size (2019 and 2025E)

2025E Total Addressable Market ⁽²⁾			\$266 Bn
2025E Serviceable Addressable Market (Based on Current Offerings)	\$9	9 Bn	
2019 Serviceable Addressable Market ⁽¹⁾	\$56 Bn		

Source: Company Research

Notes:

1. Serviceable Addressable Market Segments include Pharma, OTC, Diagnostics, Consultations and Hospital Supplies

2. In addition to the Serviceable Addressable Market Segments, Total Market Segments includes Hospital Treatment, Medical Insurance and Alternate Medicine


API Holdings Addresses One of the Largest Digital Market Opportunities



Source: Company Research

= Addressing Structural Challenges in the Indian Healthcare System

Indian Healthcare System Plagued By **Several Structural Challenges**






Lack of Data Capturing

Lack of an integrated platform offering a one-patient view

2 \checkmark •

API's Platform Targeted At Addressing Each Structural Challenge




API Holdings





API Holdings has created an Integrated Solution for all Stakeholders in the OPD Healthcare Ecosystem


Eco-system stakeholders



* PharmEasy Brand and App have been licensed to Axelia Solutions Pvt. Ltd. ("Axelia"); Axelia operates the PharmEasy marketplace; API Holdings owns 19.99% of Aarman Solutions Pvt. Ltd. which is the holding company of Axelia **In October 2021, API Holdings acquired a 49.17% stake in Marg ERP Limited, an ERP software vendor to pharmacies and wholesalers

***In September 2021, Docon Technologies, a wholly owned subsidiary of API Holdings, acquired 71.22% equity interest in Thyrocare Technologies Limited ("Thyrocare")

API Holdings is Leveraging its Leading Presence in the Sale of Products to now creating a Large Services Business



Notes:

* PharmEasy Brand and App have been licensed to Axelia Solutions Pvt. Ltd. ("Axelia"); Axelia operates the PharmEasy marketplace; API Holdings owns 19.99% of Aarman Solutions Pvt. Ltd. which is the holding company of Axelia


**In October 2021, API Holdings acquired a 49.17% stake in Marg ERP Limited, an ERP software vendor to pharmacies and wholesalers

***In September 2021, DocOn Technologies, a wholly owned subsidiary of API Holdings, acquired 71.22% equity interest in Thyrocare Technologies Limited ("Thyrocare")

1. FY2020 revenues exclude acquisitions of Thyrocare and Aknamed

Creating Integrated Platforms and Brands for Scaling our Large Products Business

Market leading pharma distribution




platform with robust operations **()** retailio Homepage 🤓 🖱 🕁 = v retailio Q Search from over 2 lakh products जिंद गी के बीच दर्द ना आ Product moov 9 4 9 Augmentin Duo 6 Click to Share P ablet(s) in strip Eastern Andhei 5 YEAR DHAMAKA Oty 14752 Exp Aug '23 Scheme: 12+1,6+0.5 Payment ₹626094 Q 🕢 🕐 = Payments Target: ₹892000 | Reward: ₹800 PTR MARGIN 26.7% ₹ 159.58 ₹223.42 Transaction Order Daily, Win Big! Farn 11.1% extra with Moxikind CV 625. 1 fe Life Enter. Earn Assured Earn Assure ₹125 Cashb 0 Õ 8 ₹125 Cashback 2 19 Compare 35 Substitut Pay Nov Pay Now By Popularity Eastern Andher PTR ₹ 159.58 Scheme: 12+1,6+0.5 MARCEN 26.7% Shree Simba Chemist, MRP ₹ 223. Bhandup 0 Overdue Desai Pharma Distributors Pvt. Ltd, PTR ₹ 144.08 ₹25.59.579.51 ₹25.50.227.51 Mumbai MARGIN 26.79 Eastern Andher EA Overdue ₹3.67.901.88 ₹3.59.687.88 esai Pharma Distributors vt. Ltd, Mumbai × Ô 6 5 0

Large, tech enabled platform for hospital procurement & supply chain


Order tracking								đ			
SmartBuy	Deltoard Orde	Payments	Product Master Analytic							_ • •	
Orders Lie	st								С	knc	amed
Supplying Investo	a.90	P binch	~ 0mm ~	Destour 15	v						
Quick Search	Press Dates from Datasates	Courses Dates Will	(Anternatives)								
Showing L 171	(Nortes)										
1145.0	R0	Derg	CENTER	AMOUNT							
• Pending	PH/WIR/20-21/PO/197	26/01/2020	MAX, Dehradum	35,000							
• Pesting	PH/MIR/20-21/PO/197	28/01/2020	MAX, Debradan	25,000							
• Panding	PH/W8/20-31/PG/197	26/01/2020	MAX, Detrocture	35,000		Ana	lyti	ics d	ashl	ooard	k
• Panding	123456	28/01/2020	MAX, Defroidum	25,000			_				
• Partial	123454	Molecules w	ith SKU Proliferation		Consumer Ci	insumption					
		Showing 1-10	f 50 Molecules		Showing 1-10 p	50 Molecules					
		MOLECULAR C	OMPOSITION No. OF 5	808	PRODUCT NAM		TRO	MPP			
		1.3-bis(hydrax	methyllurea 5000		TAB-NOVAMO	71	ICEAUNIT	35.000			
		1,3-bis(hydrox	methyljurea 5000		TAB-NOVAMO	(CV 625 50	00	35,000			
		Total Purcha	se Amount								
		25	-								
		Incluse Amount [inclused]									
		13									
		2								Pavn	nents
			Jan Feb Mar	Apr May 3	hin July 1	luig					
			Pu	rchase Order	r #234234						Clear All
			PR	DUCT					RATE	QTY	TOTAL
			Col	onlast Assura 1 P	iece Convex Maxi	Transnarent Pr	uch		20s	50	12000
				opent / 0200 0 1 1							
			Col	oplast Assura 1 P	fiece Convex Max	Transparent Po	such		20s	50	12000
			Col	oplast Assura 1 P	liece Convex Max	Transparent Pc	such		20s	50	12000
				tal Products: 1 tal Amount: 1						Review O	der


Building a Strong Portfolio of Services Across Diagnostics, Consultation and Software Services

<u>API Diagnostics:</u> Cross sell of diag. to PharmEasy customer base



<u>Retailio 3P</u>: Large retailer base enabling cross sell of 1P and diag.






Powered by ERP solution



Notes: * PharmEasy Brand and App have been licensed to Axelia Solutions Pvt. Ltd. ("Axelia"); Axelia operates the PharmEasy marketplace; API Holdings owns 19.99% of Aarman Solutions Pvt. Ltd. which is the holding company of Axelia **In October 2021, API Holdings acquired a 49.17% stake in Marg ERP Limited, an ERP software vendor to pharmacies and wholesalers


We have Delivered Strong Network & Traffic Growth across our Businesses and Brands



Notes:

* PharmEasy Brand and App have been licensed to Axelia Solutions Pvt. Ltd. ("Axelia"); Axelia operates the PharmEasy marketplace; API Holdings owns 19.99% of Aarman Solutions Pvt. Ltd. which is the holding company of Axelia ** In September 2021, DocOn Technologies, a wholly owned subsidiary of API Holdings, acquired 71.22% equity interest in Thyrocare Technologies Limited ("Thyrocare")

API Holdings Scale & Platform Strength – At a Glance



Notes:

1. For the Fiscal year 2022 basis management views of pro forma financials

2. We define GMV as follows: (i) For our products and services (other than Retailio 3P), GMV refers to our revenue for such products and services as per our books of accounts, grossed up for applicable taxes, (ii) for Retailio 3P, GMV refers to the gross merchandise value of products

and services transacted using Retailio (excluding Retailio 1P GMV)

3. For the month of March 2022

Strong and Industry Leading Consumer Engagement Metrics

PharmEasy: Share of Repeat User GMV ^{(1),(2)} PharmEasy GMV Cohorts^{(1),(2)} Cohort Retention for GMV per Retained Customer, FY19 to FY22, rebased to 1 Y1 Y2 **Y3** Y4 FY 2019 1.0x 2.8x 2.9x 3.2x 29% 36% 49% FY 2020 2.7x 1.0x 3.2x 71% 64% 51% FY 2021 1.0x 2.7x FY20 FY21 FY22 FY 2022 1.0x **Repeat User GMV New User GMV**

1. For consumers transacting on the PharmEasy Marketplace


Notes:

2. The PharmEasy Brand has been licensed to Axelia, which operates the PharmEasy marketplace. API Holdings holds a 19.99% stake in Aarman Solutions Pvt. Ltd, which is the holding company of Axelia

Strong Pharmacy Engagement Across Retailio Driving Penetration Across Geographies


Retailio Active Pharmacies

#000s



Retailio GMV Cohorts⁽¹⁾

Cohort Retention for GMV per Retained Pharmacy, FY19 to FY22, rebased to 1




API Holdings


API Holdings – FY22 Financial Overview



Achieving Massive Scale with a ~INR 135 Bn GMV in FY22




FY22 Proforma Revenue Mix ^{(1),(2)}



Notes:

- Based on management views of pro forma financial information and assumes the acquisitions of Ascent Health and Wellness Solutions Private Limited, Medlife International Private Limited, Akna Medical Private Limited and Thyrocare Technologies Limited as if these were acquired on April 1, 2020, by our Company
- Revenue is net of intercompany sales
- We define GMV as follows: (i) For our products and services (other than Retailio 3P), GMV refers to our revenue for such products and services as per our books of accounts, grossed up for applicable taxes, (ii) for Retailio 3P, GMV refers to the gross merchandise value of 3. products and services transacted using Retailio (excluding Retailio 1P GMV)

Building on Our Fast-Growing Platform Strength



Notes:

- 1. Based on management views of pro forma financial information and assumes the acquisitions of Ascent Health and Wellness Solutions Private Limited, Medlife International Private Limited, Akna Medical Private Limited and Thyrocare Technologies Limited as if these were acquired on April 1, 2020 by our Company
- 2. Revenue is net of intercompany sales
- 3. We define GMV as follows: (i) For our products and services (other than Retailio 3P), GMV refers to our revenue for such products and services as per our books of accounts, grossed up for applicable taxes, (ii) for Retailio 3P, GMV refers to the gross merchandise value of products and services transacted using Retailio (excluding Retailio 1P GMV)

Building Growth while also maintaining Positive Contribution Margins

Proforma Contribution & Adjustment EBITDA (INR MM) (1),(2)	FY2022
Revenue From Operations	63,836
Less: COGS	55,191
Gross Margins	8,645
Gross Margin %	13.5%
Less: Direct & Warehousing Costs	5,464
Contribution Margin	3,181
Contribution Margin %	5%
Less: Corporate Expenses	11,876
Adjusted EBITDA ⁽³⁾	-8,695
Adjusted EBITDA %	-13.6%

Notes:

1. Based on management views of pro forma financial information and assumes the acquisitions of Ascent Health and Wellness Solutions Private Limited, Medlife International Private Limited, Akna Medical Private Limited and Thyrocare Technologies Limited as if these were acquired on April 1, 2020, by our Company

2. Revenue is net of intercompany sales

3. Adjusted EBITDA excludes share-based payment expenses, one time performance bonus and other non-recurring costs such as legal and professional fees primarily incurred in connection with acquisitions made, raising equity and debt and filing of public offer

Thank You